Drug Insight: statins and stroke
نویسندگان
چکیده
منابع مشابه
Natural statins and stroke.
To the Editor: The comprehensive review by Furberg1 of natural statins and stroke raises a number of issues. Stroke was a secondary end point in these studies in patients with cardiovascular disease (CVD). Primary end-point trials in stroke are awaited. Surrogate markers can be valuable guides to the introduction of better therapies before large-scale trials are completed. LDL may be the best s...
متن کاملNatural statins and stroke risk.
The Burden of Stroke In the United States, '600 000 persons experience a clinical stroke (first or recurrent) annually.1 Although the case-fatality rate has declined over the past decades, it is still high. The annual death toll is '150 000, which qualifies stroke as the third leading cause of death, behind coronary heart disease (CHD) and cancer. The clinical sequelae of a stroke are often dev...
متن کاملStatins for Stroke Prevention
The occurrence of stroke increases with age, particularly affecting the older elderly, a population also at higher risk for coronary heart disease (CHD). Epidemiological and observational studies have not shown a clear association between cholesterol levels and all causes of stroke. Nonetheless, large, long-term statin trials in patients with established CHD or at high risk for CHD have shown t...
متن کاملStatins in threatened stroke.
What Is Known: Statins in Stroke Prevention Both a meta-analysis1 and the large secondary prevention trials of coronary heart disease (CHD) with simvastatin2 and with pravastatin3,4 revealed a reduction of 19% to 32% in ischemic strokes in patients with CHD. The results led to the Food and Drug Administration approval of pravastatin and simvastatin for stroke prevention in patients with CHD. Ac...
متن کاملDrug interactions and the statins.
Drug interactions commonly occur in patients receiving treatment with multiple medications. Most interactions remain unrecognized because drugs, in general, have a wide margin of safety or because the extent of change in drug levels is small when compared with the variation normally seen in clinical therapy. All drug interactions have a pharmacokinetic or pharmacodynamic basis and are predictab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Clinical Practice Cardiovascular Medicine
سال: 2005
ISSN: 1743-4297,1743-4300
DOI: 10.1038/ncpcardio0348